{ "what": "Jabbit review: registered studies that measure bone on GLP-1 drugs or cagrilintide (ClinicalTrials.gov API v2) and a DailyMed scan of 9 US GLP-1 brand labels for fracture or bone-density text", "pulled": "2026-10-20 00:56 CDT (box clock; = 01:56 ET, October 20, 2026)", "query_counts": { "intr:semaglutide": 788, "intr:tirzepatide": 303, "intr:retatrutide": 33, "intr:orforglipron": 53, "intr:liraglutide": 515, "intr:cagrilintide": 44, "term1": 141, "term2": 109, "term3": 1 }, "unique_studies_pulled": 1712, "keyword_hits": 189, "method": "Hand-review layer over ops/data/glp1-bone/ctgov-raw.json (from glp1_bone_ctgov.py) plus a DailyMed label scan\n(ops/data/glp1-bone/spl/*.xml). Every bone-flagged registry record was read by hand on 2026-10-20 (ET).\nKept = the study gives a GLP-1 drug (semaglutide, tirzepatide, liraglutide, exenatide, supaglutide, \"GLP-1 RA\" as a class)\nor cagrilintide, AND registers a bone outcome (BMD, bone mineral content, bone turnover markers, trabecular bone score,\nHR-pQCT/QCT, fracture) or names bone in its title. Writes site/research/sources/glp1-bone-ctgov-labels-2026-10-20.json. Jabbit analysis.", "summary": { "kept_total": 30, "by_design": { "rct_vs_control": [ "NCT01381926", "NCT02473809", "NCT03341429", "NCT04174755", "NCT04383197", "NCT04702516", "NCT04892199", "NCT06050577", "NCT06390501", "NCT06909006", "NCT07010432", "NCT07165158" ], "rct_other": [ "NCT05933499", "NCT07154719", "NCT07361874", "NCT07589322", "NCT07625202", "NCT07760948" ], "single_arm": [ "NCT04964388", "NCT06060392", "NCT06861439", "NCT06903923", "NCT07428746" ], "obs": [ "NCT03363464", "NCT06182852", "NCT06605287", "NCT06790160", "NCT07094568", "NCT07422987", "NCT07835360" ] }, "by_drug": { "semaglutide": [ "NCT04174755", "NCT04383197", "NCT04702516", "NCT04892199", "NCT06050577", "NCT06060392", "NCT06390501", "NCT06909006", "NCT07165158", "NCT07361874", "NCT07428746", "NCT07760948" ], "tirzepatide": [ "NCT05933499", "NCT06861439", "NCT07094568", "NCT07154719", "NCT07589322" ], "liraglutide": [ "NCT02473809", "NCT03341429" ], "exenatide": [ "NCT01381926" ], "cagrilintide": [ "NCT07010432" ], "class": [ "NCT03363464", "NCT04964388", "NCT06182852", "NCT06605287", "NCT06790160", "NCT06903923", "NCT07422987", "NCT07625202", "NCT07835360" ] }, "with_posted_results": [ "NCT01381926", "NCT04964388" ], "bone_primary_outcome": [ "NCT01381926", "NCT02473809", "NCT04702516", "NCT04964388", "NCT06050577", "NCT06182852", "NCT06861439", "NCT07010432", "NCT07094568", "NCT07165158", "NCT07422987" ], "fracture_outcome_kept": [ "NCT03363464" ], "fracture_outcome_any_study_in_pull": [ "NCT00879970", "NCT03363464", "NCT06745544" ], "novo_or_lilly_with_bone_outcome": { "NCT07010432": "Novo Nordisk A/S" }, "industry_sponsor": [ "NCT03363464", "NCT07010432" ], "recruiting_or_not_started": [ "NCT04174755", "NCT05933499", "NCT06060392", "NCT06903923", "NCT06909006", "NCT07010432", "NCT07094568", "NCT07154719", "NCT07165158", "NCT07361874", "NCT07428746", "NCT07589322", "NCT07625202", "NCT07760948", "NCT07835360" ], "tirzepatide_vs_placebo_randomized": [], "retatrutide_or_orforglipron": [], "retatrutide_or_orforglipron_studies_in_pull": 86, "labels_with_fracture_text": [ "wegovy" ], "labels_scanned": [ "foundayo", "mounjaro", "ozempic", "rybelsus", "saxenda", "trulicity", "victoza", "wegovy", "zepbound" ] }, "studies": [ { "nct": "NCT01381926", "drug": "exenatide", "design": "rct_vs_control", "what": "Exenatide vs placebo, postmenopausal women with type 2 diabetes; bone turnover markers primary (UAB)", "title": "Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist", "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "status": "TERMINATED", "has_results": true, "enrollment": 14, "enrollment_type": "ACTUAL", "start": "2011-02", "primary_completion": "2015-08", "min_age": "45 Years", "max_age": null, "bone_primary": [ "Determine Changes in Bone Resorption Markers During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.", "Determine Changes in Bone Turnover Markers by Serum N-Telo Peptide During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.", "Determine Changes in Bone Turnover Markers by Tartrate-Resistant Acid Phosphatase 5b (TRACP5b) During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM." ], "bone_secondary": [], "fracture_outcome": false }, { "nct": "NCT02473809", "drug": "liraglutide", "design": "rct_vs_control", "what": "Liraglutide vs placebo; CTX primary, DXA BMD, QCT/HR-pQCT (Aarhus)", "title": "The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function", "sponsor": "University of Aarhus", "sponsor_class": "OTHER", "status": "COMPLETED", "has_results": false, "enrollment": 60, "enrollment_type": "ACTUAL", "start": "2015-08", "primary_completion": "2017-10", "min_age": "30 Years", "max_age": "90 Years", "bone_primary": [ "Change in collagen I cross-linked C-terminal telopeptide measured in serum" ], "bone_secondary": [ "Change in BMD evaluated by DXA", "Change in bone alkaline phosphatase measured in serum", "Change in bone structure evaluated by QCT and HRpQCT", "Change in osteocalcin measured in serum", "Change in procollagen type I N-terminal propeptide measured in serum" ], "fracture_outcome": false }, { "nct": "NCT03341429", "drug": "liraglutide", "design": "rct_vs_control", "what": "Liraglutide 3.0 mg vs placebo after poor weight loss; BMD secondary (UCL)", "title": "Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response", "sponsor": "University College, London", "sponsor_class": "OTHER", "status": "COMPLETED", "has_results": false, "enrollment": 70, "enrollment_type": "ACTUAL", "start": "2018-08-22", "primary_completion": "2019-11-28", "min_age": "18 Years", "max_age": "64 Years", "bone_primary": [], "bone_secondary": [ "Bone mineral density" ], "fracture_outcome": false }, { "nct": "NCT03363464", "drug": "class", "design": "obs", "what": "Empagliflozin vs DPP-4 inhibitors or GLP-1 drugs in claims data; bone fracture secondary (Boehringer Ingelheim; GLP-1 drugs are a comparison group)", "title": "Comparative Effectiveness of Empagliflozin in the US", "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "status": "COMPLETED", "has_results": false, "enrollment": 230000, "enrollment_type": "ACTUAL", "start": "2017-10-16", "primary_completion": "2026-07-09", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Bone fracture" ], "fracture_outcome": true }, { "nct": "NCT04174755", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide vs standard care in people with HIV; BMD secondary (UCD)", "title": "Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV", "sponsor": "University College Dublin", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 80, "enrollment_type": "ESTIMATED", "start": "2022-06-22", "primary_completion": "2027-01", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Changes in bone mineral density (BMD) and total body composition" ], "fracture_outcome": false }, { "nct": "NCT04383197", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide, endurance exercise, or both; plasma bone markers secondary (Copenhagen)", "title": "Exercise and GLP-1 RA on Insulin Secretion", "sponsor": "University of Copenhagen", "sponsor_class": "OTHER", "status": "UNKNOWN", "has_results": false, "enrollment": 30, "enrollment_type": "ESTIMATED", "start": "2019-12-10", "primary_completion": "2021-08", "min_age": "40 Years", "max_age": "70 Years", "bone_primary": [], "bone_secondary": [ "Changes in plasma bone markers" ], "fracture_outcome": false }, { "nct": "NCT04702516", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide 1.0 mg vs placebo in adults at increased fracture risk; P1NP primary (Odense; published 2024 in eClinicalMedicine, PMID 38737002)", "title": "The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture", "sponsor": "Morten Frost", "sponsor_class": "OTHER", "status": "UNKNOWN", "has_results": false, "enrollment": 64, "enrollment_type": "ESTIMATED", "start": "2021-03-24", "primary_completion": "2022-08-31", "min_age": "40 Years", "max_age": "85 Years", "bone_primary": [ "Procollagen type 1 N-terminal propeptide (P1NP)" ], "bone_secondary": [ "Bone formation rate", "Bone mineral density (BMD)", "Bone specific alkaline phosphatase (BALP)", "Bone volume", "Collagen 1 cross link C-terminal telopeptide (CTX)", "Cortical volumetric BMD", "Estimated bone strength", "Osteocalcin", "Total volumetric BMD", "Trabecular thickness", "Trabecular volumetric BMD" ], "fracture_outcome": false }, { "nct": "NCT04892199", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide vs placebo in people on antipsychotics; bone markers and bone density secondary", "title": "Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?", "sponsor": "Anders Fink-Jensen, MD, DMSci", "sponsor_class": "OTHER", "status": "UNKNOWN", "has_results": false, "enrollment": 104, "enrollment_type": "ESTIMATED", "start": "2021-09-01", "primary_completion": "2026-03-01", "min_age": "18 Years", "max_age": "65 Years", "bone_primary": [], "bone_secondary": [ "Bone Markers (Blood sampling)", "Bone density" ], "fracture_outcome": false }, { "nct": "NCT04964388", "drug": "class", "design": "single_arm", "what": "GLP-1 drug in postmenopausal women with type 2 diabetes; trabecular bone score primary (Mississippi; terminated at 5 people)", "title": "Effect of GLP-1 Receptor Agonists on Trabecular Bone Score", "sponsor": "University of Mississippi Medical Center", "sponsor_class": "OTHER", "status": "TERMINATED", "has_results": true, "enrollment": 5, "enrollment_type": "ACTUAL", "start": "2021-11-09", "primary_completion": "2023-05-01", "min_age": "55 Years", "max_age": null, "bone_primary": [ "Trabecular Bone Score" ], "bone_secondary": [ "Inflammatory Markers and Bone Resorption Markers", "Sclerostin and Bone Formation Markers" ], "fracture_outcome": false }, { "nct": "NCT05933499", "drug": "tirzepatide", "design": "rct_other", "what": "Tirzepatide + bimagrumab vs tirzepatide + placebo vs bimagrumab + placebo; 'bone' in title, lean mass primary (Massachusetts General Hospital)", "title": "Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity", "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 63, "enrollment_type": "ESTIMATED", "start": "2025-11-05", "primary_completion": "2028-12-31", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [], "fracture_outcome": false }, { "nct": "NCT06050577", "drug": "semaglutide", "design": "rct_vs_control", "what": "Oral semaglutide (Rybelsus) vs placebo in type 2 diabetes; P1NP primary (Odense)", "title": "The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial", "sponsor": "Odense University Hospital", "sponsor_class": "OTHER", "status": "ACTIVE_NOT_RECRUITING", "has_results": false, "enrollment": 64, "enrollment_type": "ESTIMATED", "start": "2024-06-07", "primary_completion": "2027-01-15", "min_age": "50 Years", "max_age": "85 Years", "bone_primary": [ "Procollagen type 1 N-terminal propeptide (P1NP)" ], "bone_secondary": [ "Bone formation rate", "Bone mineral density (BMD)", "Bone specific alkaline phosphatase (BALP)", "Bone volume", "Collagen 1 cross link C-terminal telopeptide (CTX)", "Cortical volumetric BMD", "Estimated bone strength", "Osteocalcin", "Total volumetric BMD", "Trabecular thickness", "Trabecular volumetric BMD" ], "fracture_outcome": false }, { "nct": "NCT06060392", "drug": "semaglutide", "design": "single_arm", "what": "Oral semaglutide after liver transplant; bone mineral content secondary (Medanta)", "title": "Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus", "sponsor": "Medanta, The Medicity, India", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 50, "enrollment_type": "ESTIMATED", "start": "2023-10-30", "primary_completion": "2025-09-02", "min_age": "30 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Change in bone mineral content" ], "fracture_outcome": false }, { "nct": "NCT06182852", "drug": "class", "design": "obs", "what": "GLP-1 drugs and bone metabolism in diabetes; BMD primary (Nanjing)", "title": "The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus", "sponsor": "Nanjing First Hospital, Nanjing Medical University", "sponsor_class": "OTHER", "status": "UNKNOWN", "has_results": false, "enrollment": 330, "enrollment_type": "ESTIMATED", "start": "2024-01-01", "primary_completion": "2024-12-31", "min_age": "18 Years", "max_age": null, "bone_primary": [ "Bone metabolism", "Bone mineral density" ], "bone_secondary": [], "fracture_outcome": false }, { "nct": "NCT06390501", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide vs placebo on energy expenditure; bone mass secondary (Shenzhen)", "title": "The Effect of Weekly Semaglutide Treatment on Energy Expenditure", "sponsor": "Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences", "sponsor_class": "OTHER", "status": "COMPLETED", "has_results": false, "enrollment": 60, "enrollment_type": "ACTUAL", "start": "2024-04-01", "primary_completion": "2025-08-15", "min_age": "18 Years", "max_age": "60 Years", "bone_primary": [], "bone_secondary": [ "Bone mass" ], "fracture_outcome": false }, { "nct": "NCT06605287", "drug": "class", "design": "obs", "what": "Supaglutide in type 2 diabetes; DXA T-score (Nanjing)", "title": "The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients", "sponsor": "Nanjing First Hospital, Nanjing Medical University", "sponsor_class": "OTHER", "status": "UNKNOWN", "has_results": false, "enrollment": 100, "enrollment_type": "ESTIMATED", "start": "2023-03-13", "primary_completion": "2024-12-31", "min_age": "18 Years", "max_age": "75 Years", "bone_primary": [], "bone_secondary": [ "Change in Dex bone density (T value)" ], "fracture_outcome": false }, { "nct": "NCT06790160", "drug": "class", "design": "obs", "what": "Anti-obesity medication users; total bone mineral content (Texas Tech)", "title": "Study of Patients Being Treated With Anti-obesity Medication", "sponsor": "Texas Tech University", "sponsor_class": "OTHER", "status": "ACTIVE_NOT_RECRUITING", "has_results": false, "enrollment": 100, "enrollment_type": "ACTUAL", "start": "2025-01-31", "primary_completion": "2028-03", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Change in Total Bone Mineral Content" ], "fracture_outcome": false }, { "nct": "NCT06861439", "drug": "tirzepatide", "design": "single_arm", "what": "Tirzepatide for 9 months, age 65+; total hip and lumbar spine BMD among primary outcomes (Wake Forest)", "title": "GLP-1s to Enhance Lasting Optimal Weight", "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "status": "ACTIVE_NOT_RECRUITING", "has_results": false, "enrollment": 40, "enrollment_type": "ACTUAL", "start": "2025-07-07", "primary_completion": "2027-10-30", "min_age": "65 Years", "max_age": null, "bone_primary": [ "Change in lumbar spine bone mineral density", "Change in total hip bone mineral density" ], "bone_secondary": [ "Change in bone-specific alkaline phosphatase (BALP)", "Change in c-telopeptide of type 1 collagen (CTX)", "Change in hip bone strength", "Change in osteocalcin", "Change in procollagen type 1 n-terminal propeptide (P1NP)", "Change in total volumetric bone mineral density of the hip", "Change in total volumetric bone mineral density of the radius", "Change in total volumetric bone mineral density of the tibia" ], "fracture_outcome": false }, { "nct": "NCT06903923", "drug": "class", "design": "single_arm", "what": "GLP-1 drugs in 12-21 year olds; hip/spine BMD, HR-pQCT and bone markers (University of Virginia)", "title": "Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy", "sponsor": "University of Virginia", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 120, "enrollment_type": "ESTIMATED", "start": "2025-07-31", "primary_completion": "2030-02-28", "min_age": "12 Years", "max_age": "21 Years", "bone_primary": [], "bone_secondary": [ "24-month change in P1NP and CTX", "24-month change in hormones known to impact bone (insulin, ghrelin, PYY, oxytocin, estrogens and sclerostin)", "24-month change in radial and tibial trabecular vBMD", "24-month change in total hip and spine areal BMD" ], "fracture_outcome": false }, { "nct": "NCT06909006", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide 2.4 mg vs placebo in type 1 diabetes; bone density secondary", "title": "Semaglutide Treatment in Type 1 Diabetes", "sponsor": "Nordsjaellands Hospital", "sponsor_class": "OTHER", "status": "NOT_YET_RECRUITING", "has_results": false, "enrollment": 122, "enrollment_type": "ESTIMATED", "start": "2025-10", "primary_completion": "2028-06", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Bone density (through bone mineral content)" ], "fracture_outcome": false }, { "nct": "NCT07010432", "drug": "cagrilintide", "design": "rct_vs_control", "what": "Cagrilintide vs semaglutide vs CagriSema vs placebo, postmenopausal women 50-70; total hip volumetric BMD by QCT primary (Novo Nordisk)", "title": "The Role of the Amylin Analogue Cagrilintide in Bone Metabolism", "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "status": "RECRUITING", "has_results": false, "enrollment": 144, "enrollment_type": "ESTIMATED", "start": "2025-06-12", "primary_completion": "2028-05-03", "min_age": "50 Years", "max_age": "70 Years", "bone_primary": [ "Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT)" ], "bone_secondary": [ "Relative change in the Ki (bone turnover) of the femoral neck assessed by fluoride - PET", "Relative change in the Ki (bone turnover) of the femoral neck assessed by fluoride - positron emission tomography (PET)", "Relative changes in C-terminal telopeptide of type I collagen (CTX-1) and procollagen type 1 N-terminal propeptide (P1NP)", "Relative changes in CTX-1 and P1NP", "Relative changes in trabecular thickness assessed by PCCT", "Relative changes in vBMD of the L1 - L4 vertebrae assessed by QCT", "Relative changes in vBMD of the lumbar 1 (L1) - L4 vertebrae assessed by QCT", "Relative changes in vBMD of the radius assessed by QCT" ], "fracture_outcome": false }, { "nct": "NCT07094568", "drug": "tirzepatide", "design": "obs", "what": "Tirzepatide vs liraglutide; CTX primary, BMD (Athens)", "title": "Tirzepatide vs Liraglutide in Bone", "sponsor": "National and Kapodistrian University of Athens", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 72, "enrollment_type": "ESTIMATED", "start": "2025-05-23", "primary_completion": "2026-12-30", "min_age": "30 Years", "max_age": "65 Years", "bone_primary": [ "Change in serum CTX concentration" ], "bone_secondary": [ "Change in Bone Mineral Density (BMD)" ], "fracture_outcome": false }, { "nct": "NCT07154719", "drug": "tirzepatide", "design": "rct_other", "what": "Tirzepatide + lifestyle toolkit vs tirzepatide alone; bone turnover markers secondary (Pennington)", "title": "GLP-1R Actions on Muscle and the Skeleton", "sponsor": "Pennington Biomedical Research Center", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 50, "enrollment_type": "ESTIMATED", "start": "2025-10-09", "primary_completion": "2027-02-01", "min_age": "18 Years", "max_age": "50 Years", "bone_primary": [], "bone_secondary": [ "C-Terminal Telopeptide of type I collagen (CTX-1)", "Osteocalcin", "Procollagen 1 N-terminal peptide (P1NP)" ], "fracture_outcome": false }, { "nct": "NCT07165158", "drug": "semaglutide", "design": "rct_vs_control", "what": "Semaglutide + metformin vs metformin, age 50-75; lumbar BMD primary (Xiamen)", "title": "The Effect of Semaglutide on Bone Health", "sponsor": "The First Affiliated Hospital of Xiamen University", "sponsor_class": "OTHER", "status": "NOT_YET_RECRUITING", "has_results": false, "enrollment": 150, "enrollment_type": "ESTIMATED", "start": "2025-09-15", "primary_completion": "2026-12-31", "min_age": "50 Years", "max_age": "75 Years", "bone_primary": [ "lumbar bone mineral density" ], "bone_secondary": [], "fracture_outcome": false }, { "nct": "NCT07361874", "drug": "semaglutide", "design": "rct_other", "what": "Adrenalectomy vs semaglutide for mild autonomous cortisol secretion; BMD secondary (UT Southwestern)", "title": "IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion", "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 75, "enrollment_type": "ESTIMATED", "start": "2026-03-05", "primary_completion": "2030-05-31", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Change in bone mineral density, mg/cm³" ], "fracture_outcome": false }, { "nct": "NCT07422987", "drug": "class", "design": "obs", "what": "GLP-1 drugs in midlife women; BMD primary (University of Kansas)", "title": "GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women", "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "status": "ACTIVE_NOT_RECRUITING", "has_results": false, "enrollment": 50, "enrollment_type": "ESTIMATED", "start": "2026-02-12", "primary_completion": "2027-06-30", "min_age": "35 Years", "max_age": "60 Years", "bone_primary": [ "Bone mineral density (BMD)" ], "bone_secondary": [ "Estrogen level role in BMD changes during GLP-1RA therapy" ], "fracture_outcome": false }, { "nct": "NCT07428746", "drug": "semaglutide", "design": "single_arm", "what": "Semaglutide in older women with diabetes and osteosarcopenia; bone turnover markers (Emory)", "title": "Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes", "sponsor": "Emory University", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 20, "enrollment_type": "ESTIMATED", "start": "2026-05-07", "primary_completion": "2028-11", "min_age": "65 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Change in bone turnover markers" ], "fracture_outcome": false }, { "nct": "NCT07589322", "drug": "tirzepatide", "design": "rct_other", "what": "Tirzepatide vs semaglutide; BMD, P1NP, CTX secondary (Tri-Service General Hospital, Taiwan)", "title": "Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs", "sponsor": "Tri-Service General Hospital (TSGH)", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 120, "enrollment_type": "ESTIMATED", "start": "2026-03-31", "primary_completion": "2028-09-30", "min_age": "20 Years", "max_age": "65 Years", "bone_primary": [], "bone_secondary": [ "Change in bone mineral density (g/cm²)", "Change in serum CTX-1 (ng/mL)", "Change in serum P1NP (ng/mL)" ], "fracture_outcome": false }, { "nct": "NCT07625202", "drug": "class", "design": "rct_other", "what": "Creatine vs placebo during resistance training in people starting a GLP-1 drug; BMD secondary (Saskatchewan)", "title": "Creatine Supplementation During GLP-1a Therapy", "sponsor": "University of Saskatchewan", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 40, "enrollment_type": "ESTIMATED", "start": "2026-05-25", "primary_completion": "2027-05-30", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Change in femoral neck bone mineral density (g/cm squared)", "Change in lumbar spine bone mineral density (g/cm squared)", "Change in total hip bone mineral density (g/cm squared)", "Change in whole body bone mineral density (g/cm squared)" ], "fracture_outcome": false }, { "nct": "NCT07760948", "drug": "semaglutide", "design": "rct_other", "what": "HMB + vitamin D vs placebo in older adults starting semaglutide; BMD and trabecular bone score secondary (Vanderbilt)", "title": "HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide", "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "status": "NOT_YET_RECRUITING", "has_results": false, "enrollment": 90, "enrollment_type": "ESTIMATED", "start": "2026-12-01", "primary_completion": "2029-11-30", "min_age": "65 Years", "max_age": "85 Years", "bone_primary": [], "bone_secondary": [ "Change in Bone Mineral Density", "Change in Trabecular Bone Score" ], "fracture_outcome": false }, { "nct": "NCT07835360", "drug": "class", "design": "obs", "what": "Body composition after starting GLP-1 drugs; spine and hip BMD (Mexico City)", "title": "Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes", "sponsor": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", "sponsor_class": "OTHER", "status": "RECRUITING", "has_results": false, "enrollment": 200, "enrollment_type": "ESTIMATED", "start": "2026-07-10", "primary_completion": "2029-07", "min_age": "18 Years", "max_age": null, "bone_primary": [], "bone_secondary": [ "Change in Hip Bone Mineral Density", "Change in Lumbar Spine Bone Mineral Density" ], "fracture_outcome": false } ], "excluded": { "NCT05597202": "semaglutide; 'bone marrow aspirates' are a blood-stem-cell outcome, not bone", "NCT02928679": "liraglutide in knee osteoarthritis; 'bone marrow lesions' are a joint MRI outcome", "NCT07845994": "semaglutide in children with hypothalamic obesity; 'bone age' is a growth outcome", "NCT06426446": "Wegovy users weighed on a connected bioimpedance scale; scale 'bone mass' is an estimate, not a bone measurement", "NCT06468748": "withdrawn before enrolling", "NCT07156331": "no bone outcome registered (matched on 'skeletal muscle')", "NCT07554417": "no bone outcome registered (matched on 'skeletal muscle')", "NCT07874828": "no bone outcome registered", "NCT04626323": "gastric bypass vs medical therapy; no GLP-1 drug specified", "NCT02598791": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03526289": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT05177653": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06895408": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06722560": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03159741": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03195257": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03573934": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03574064": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03728959": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03845179": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03867656": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT03954873": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT04792762": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT05181150": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT05391581": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06137586": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06143267": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06194955": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06186063": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06790225": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT07254988": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT07679516": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06334172": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06881459": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT06419686": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug", "NCT01531907": "infusion physiology study of native gut hormones (GIP, GLP-1, GLP-2, amylin, oxytocin or similar), not a GLP-1 drug" }, "labels": [ { "brand": "foundayo", "setid": "8ac446c5-feba-474f-a103-23facb9b5c62", "version": "10", "effective": "20260729", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "mounjaro", "setid": "d2d7da5d-ad07-4228-955f-cf7e355c8cc0", "version": "40", "effective": "20260827", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "ozempic", "setid": "adec4fd2-6858-4c99-91d4-531f5f2a2d79", "version": "20", "effective": "20260601", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "rybelsus", "setid": "27f15fac-7d98-4114-a2ec-92494a91da98", "version": "14", "effective": "20260130", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "saxenda", "setid": "3946d389-0926-4f77-a708-0acb8153b143", "version": "22", "effective": "20260225", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "trulicity", "setid": "463050bd-2b1c-40f5-b3c3-0a04bb433309", "version": "62", "effective": "20260616", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "victoza", "setid": "5a9ef4ea-c76a-4d34-a604-27c5b505f5a4", "version": "31", "effective": "20251014", "fracture_sentences": [], "mentions_bone_mineral_density": false }, { "brand": "wegovy", "setid": "ee06186f-2aa3-4990-a760-757579d8f77b", "version": "19", "effective": "20260618", "fracture_sentences": [ " Fractures In the CV outcomes trial in adults, more fractures of the hip and pelvis were reported on WEGOVY than on placebo in female patients: 1% (24/2,448) vs.", " Fractures were reported in both males and females with a median age of 61 years (range, 44 to 75).", " In a clinical trial in adults with MASH, fractures occurred in 4.", " In the CV outcomes trial, patients aged 75 years and older reported more hip and pelvis fractures in the WEGOVY injection-treated patients than placebo-treated patients." ], "mentions_bone_mineral_density": false }, { "brand": "zepbound", "setid": "487cd7e7-434c-4925-99fa-aa80b1cc776b", "version": "40", "effective": "20260828", "fracture_sentences": [], "mentions_bone_mineral_density": false } ] }